OA11312A - Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor. - Google Patents

Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor. Download PDF

Info

Publication number: OA11312A
Authority: OA; OAPI
Prior art keywords: composition according; compound; daims; insulin; theadministration
Prior art date: 1997-07-18

Application number

OA1200000013A

Other languages

English (en)

Inventor

Robin Edwin Buckingham

Stephen Alistair Smith

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-18

Filing date

2000-01-18

Publication date

2003-10-24

2000-01-18 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2003-10-24 Publication of OA11312A publication Critical patent/OA11312A/en

Links

229940122199 Insulin secretagogue Drugs 0.000 title claims abstract description 20
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 title claims description 9
206010012601 diabetes mellitus Diseases 0.000 title abstract description 4
229940123464 Thiazolidinedione Drugs 0.000 title description 7
239000003112 inhibitor Substances 0.000 title description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 74
102000004877 Insulin Human genes 0.000 claims abstract description 37
108090001061 Insulin Proteins 0.000 claims abstract description 37
229940125396 insulin Drugs 0.000 claims abstract description 37
239000000203 mixture Substances 0.000 claims abstract description 31
231100000489 sensitizer Toxicity 0.000 claims abstract description 28
239000003795 chemical substances by application Substances 0.000 claims abstract description 24
229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims abstract description 19
239000003888 alpha glucosidase inhibitor Substances 0.000 claims abstract description 19
230000002058 anti-hyperglycaemic effect Effects 0.000 claims abstract description 15
150000001875 compounds Chemical class 0.000 claims description 55
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 8
-1 glibomuride Chemical compound 0.000 claims description 5
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical group O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 4
BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims description 4
229960002632 acarbose Drugs 0.000 claims description 4
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 4
YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims description 4
229960004580 glibenclamide Drugs 0.000 claims description 4
229960000346 gliclazide Drugs 0.000 claims description 4
229960001381 glipizide Drugs 0.000 claims description 4
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 4
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical group C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims description 4
FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 3
102100024295 Maltase-glucoamylase Human genes 0.000 claims description 3
IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 claims description 3
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 claims description 3
108010028144 alpha-Glucosidases Proteins 0.000 claims description 3
229960004346 glimepiride Drugs 0.000 claims description 3
WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 3
229960001110 miglitol Drugs 0.000 claims description 3
229960002354 repaglinide Drugs 0.000 claims description 3
229960002277 tolazamide Drugs 0.000 claims description 3
OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 claims description 3
229960005371 tolbutamide Drugs 0.000 claims description 3
LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 claims description 2
RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims description 2
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical group C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 2
229960001466 acetohexamide Drugs 0.000 claims description 2
VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 claims description 2
229960003362 carbutamide Drugs 0.000 claims description 2
VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 claims description 2
229960001761 chlorpropamide Drugs 0.000 claims description 2
229950009226 ciglitazone Drugs 0.000 claims description 2
229950000269 emiglitate Drugs 0.000 claims description 2
NWWORXYTJRPSMC-QKPAOTATSA-N ethyl 4-[2-[(2r,3r,4r,5s)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 NWWORXYTJRPSMC-QKPAOTATSA-N 0.000 claims description 2
229960003468 gliquidone Drugs 0.000 claims description 2
229950008402 glisentide Drugs 0.000 claims description 2
NSJYMFYVNWVGON-UHFFFAOYSA-N glisentide Chemical compound COC1=CC=CC=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCC2)C=C1 NSJYMFYVNWVGON-UHFFFAOYSA-N 0.000 claims description 2
229950005319 glisolamide Drugs 0.000 claims description 2
GZKDXUIWCNCNBJ-UHFFFAOYSA-N glisolamide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NC2CCCCC2)=N1 GZKDXUIWCNCNBJ-UHFFFAOYSA-N 0.000 claims description 2
229960003236 glisoxepide Drugs 0.000 claims description 2
ZKUDBRCEOBOWLF-UHFFFAOYSA-N glisoxepide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NN2CCCCCC2)=N1 ZKUDBRCEOBOWLF-UHFFFAOYSA-N 0.000 claims description 2
BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims description 2
229960005095 pioglitazone Drugs 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
229960001641 troglitazone Drugs 0.000 claims description 2
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 claims 1
238000000034 method Methods 0.000 abstract description 24
241000124008 Mammalia Species 0.000 abstract description 2
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1
239000003981 vehicle Substances 0.000 description 6
239000013543 active substance Substances 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
230000000694 effects Effects 0.000 description 5
230000002641 glycemic effect Effects 0.000 description 5
239000003937 drug carrier Substances 0.000 description 4
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 4
230000000580 secretagogue effect Effects 0.000 description 4
239000003826 tablet Substances 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
241000220479 Acacia Species 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
206010018429 Glucose tolerance impaired Diseases 0.000 description 2
108010023302 HDL Cholesterol Proteins 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
102000004366 Glucosidases Human genes 0.000 description 1
108010056771 Glucosidases Proteins 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
206010060378 Hyperinsulinaemia Diseases 0.000 description 1
238000008214 LDL Cholesterol Methods 0.000 description 1
108010028554 LDL Cholesterol Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000016267 Leptin Human genes 0.000 description 1
108010092277 Leptin Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010036049 Polycystic ovaries Diseases 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000011149 active material Substances 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
235000010210 aluminium Nutrition 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
229950002375 englitazone Drugs 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
206010061989 glomerulosclerosis Diseases 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000035879 hyperinsulinaemia Effects 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
229940039781 leptin Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
201000009925 nephrosclerosis Diseases 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
201000010065 polycystic ovary syndrome Diseases 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
238000007789 sealing Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000002278 tabletting lubricant Substances 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)

OA1200000013A 1997-07-18 2000-01-18 Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor. OA11312A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB9715298A GB9715298D0 (en)	1997-07-18	1997-07-18	Novel method of treatment

Publications (1)

Publication Number	Publication Date
OA11312A true OA11312A (en)	2003-10-24

Family

ID=10816170

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200000013A OA11312A (en)	1997-07-18	2000-01-18	Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor.

Country Status (27)

Country	Link
EP (1)	EP1001784A1 (fr)
JP (1)	JP2001510160A (fr)
KR (1)	KR20010021952A (fr)
CN (1)	CN1263467A (fr)
AP (1)	AP2000001735A0 (fr)
AR (2)	AR016350A1 (fr)
AU (1)	AU8449098A (fr)
BG (1)	BG104062A (fr)
BR (1)	BR9810292A (fr)
CA (1)	CA2297133A1 (fr)
CO (1)	CO4940489A1 (fr)
DZ (1)	DZ2563A1 (fr)
EA (1)	EA200000140A1 (fr)
GB (1)	GB9715298D0 (fr)
HU (1)	HUP0003626A3 (fr)
ID (1)	ID23804A (fr)
IL (1)	IL133907A0 (fr)
MA (1)	MA24608A1 (fr)
NO (1)	NO20000230L (fr)
OA (1)	OA11312A (fr)
PE (1)	PE99499A1 (fr)
PL (1)	PL338140A1 (fr)
SK (1)	SK612000A3 (fr)
TR (1)	TR200000133T2 (fr)
UY (1)	UY25101A1 (fr)
WO (1)	WO1999003478A1 (fr)
ZA (1)	ZA986364B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI238064B (en) *	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
US7045519B2 (en)	1998-06-19	2006-05-16	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
CA2349865C (fr) *	1999-06-21	2014-08-19	Eli Lilly And Company	Utilisation combinee de thiazolidinediones et de peptide-1 de type glucagone et d'agonistes de ces derniers pour traiter l'instabilite metabolique associee aux diabetes non insulino-dependants
ES2487897T3 (es) *	2000-01-21	2014-08-25	Novartis Ag	Combinaciones que consisten de inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
US20030040490A1 (en) *	2000-02-24	2003-02-27	Yasuo Sugiyama	Drugs containing combined active ingredients
JP4917712B2 (ja) *	2000-02-24	2012-04-18	武田薬品工業株式会社	併用医薬
EP1738751B1 (fr)	2001-01-12	2011-05-11	Sun Pharma Advanced Research Company Ltd	système de libération espacée de médicaments
FR2832930A1 (fr) *	2001-12-03	2003-06-06	Lipha	Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
KR100952090B1 (ko)	2003-10-31	2010-04-13	다케다 야쿠힌 고교 가부시키가이샤	인슐린 감작제, 인슐린 분비촉진제 및 폴리옥시에틸렌소르비탄 지방산 에스테르를 함유하는 고체 제제
CN101103993B (zh) *	2006-07-14	2011-03-30	北京华安佛医药研究中心有限公司	降糖药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2479492A (en) *	1991-08-26	1993-03-16	Upjohn Company, The	Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone glibenclamide or glimepiride
US5917052A (en) *	1994-09-28	1999-06-29	Shaman Pharmaceuticals, Inc.	Hypoglycemic agent from cryptolepis
TWI238064B (en) *	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes

1997
- 1997-07-18 GB GB9715298A patent/GB9715298D0/en active Pending
1998
- 1998-07-15 DZ DZ980173A patent/DZ2563A1/fr active
- 1998-07-16 MA MA25172A patent/MA24608A1/fr unknown
- 1998-07-16 PL PL98338140A patent/PL338140A1/xx unknown
- 1998-07-16 WO PCT/GB1998/002112 patent/WO1999003478A1/fr not_active Ceased
- 1998-07-16 AU AU84490/98A patent/AU8449098A/en not_active Abandoned
- 1998-07-16 HU HU0003626A patent/HUP0003626A3/hu unknown
- 1998-07-16 EP EP98935129A patent/EP1001784A1/fr not_active Withdrawn
- 1998-07-16 ID IDW20000077A patent/ID23804A/id unknown
- 1998-07-16 PE PE1998000630A patent/PE99499A1/es not_active Application Discontinuation
- 1998-07-16 AR ARP980103482A patent/AR016350A1/es unknown
- 1998-07-16 EA EA200000140A patent/EA200000140A1/ru unknown
- 1998-07-16 IL IL13390798A patent/IL133907A0/xx unknown
- 1998-07-16 KR KR1020007000517A patent/KR20010021952A/ko not_active Withdrawn
- 1998-07-16 CN CN98807147A patent/CN1263467A/zh active Pending
- 1998-07-16 JP JP2000502777A patent/JP2001510160A/ja active Pending
- 1998-07-16 CA CA002297133A patent/CA2297133A1/fr not_active Abandoned
- 1998-07-16 BR BR9810292-3A patent/BR9810292A/pt not_active IP Right Cessation
- 1998-07-16 SK SK61-2000A patent/SK612000A3/sk unknown
- 1998-07-16 TR TR2000/00133T patent/TR200000133T2/xx unknown
- 1998-07-17 UY UY25101A patent/UY25101A1/es not_active Application Discontinuation
- 1998-07-17 CO CO98040749A patent/CO4940489A1/es unknown
- 1998-07-17 ZA ZA9806364A patent/ZA986364B/xx unknown
1999
- 1999-06-28 AR ARP990103110A patent/AR019724A2/es unknown
2000
- 2000-01-06 BG BG104062A patent/BG104062A/xx unknown
- 2000-01-14 AP APAP/P/2000/001735A patent/AP2000001735A0/en unknown
- 2000-01-17 NO NO20000230A patent/NO20000230L/no not_active Application Discontinuation
- 2000-01-18 OA OA1200000013A patent/OA11312A/en unknown

Also Published As

Publication number	Publication date
NO20000230D0 (no)	2000-01-17
AR019724A2 (es)	2002-03-13
PL338140A1 (en)	2000-09-25
IL133907A0 (en)	2001-04-30
NO20000230L (no)	2000-01-17
BR9810292A (pt)	2000-09-19
SK612000A3 (en)	2000-07-11
CN1263467A (zh)	2000-08-16
UY25101A1 (es)	2000-12-29
DZ2563A1 (fr)	2003-02-15
AU8449098A (en)	1999-02-10
KR20010021952A (ko)	2001-03-15
HUP0003626A2 (hu)	2001-05-28
EP1001784A1 (fr)	2000-05-24
WO1999003478A1 (fr)	1999-01-28
JP2001510160A (ja)	2001-07-31
HUP0003626A3 (en)	2001-12-28
ID23804A (id)	2000-05-11
GB9715298D0 (en)	1997-09-24
TR200000133T2 (tr)	2000-09-21
PE99499A1 (es)	1999-12-18
BG104062A (en)	2000-11-30
AP2000001735A0 (en)	2000-01-16
AR016350A1 (es)	2001-07-04
EA200000140A1 (ru)	2000-06-26
ZA986364B (en)	2000-01-17
CA2297133A1 (fr)	1999-01-28
CO4940489A1 (es)	2000-07-24
MA24608A1 (fr)	1999-04-01

Publication	Publication Date	Title
OA11516A (en)	2004-02-04	Treatment of diabetes with thiazolidinedione and metformin.
EP1001783B1 (fr)	2005-10-05	Traitement du diabete avec du thiazolidinedione, un secretagogue d'insuline et du biguanide
US20080058388A1 (en)	2008-03-06	Treatment of diabetes with thiazolidinedione and sulphonylurea
OA11312A (en)	2003-10-24	Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor.
AU743269B2 (en)	2002-01-24	Treatment of diabetes with thiazolidinedione and sulphonylurea
AU8539298A (en)	1999-01-04	Treatment of diabetes with thiazolidinedione and sulphonylurea
AU8799998A (en)	1999-01-04	Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
US20020016287A1 (en)	2002-02-07	Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
US20030073645A1 (en)	2003-04-17	Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
AU1540002A (en)	2002-03-21	Treatment of diabetes with thiazolidinedione and sulphonylurea
US20030092750A1 (en)	2003-05-15	Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
HK1091393A (en)	2007-01-19	Treatment of diabetes with thiazolidinedione and sulphonylurea
AU2928002A (en)	2002-05-16	Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
HK1028550B (en)	2006-05-19	Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
AU2005227371A1 (en)	2005-11-24	Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide